Sudeep Pharma
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Sudeep Pharma is navigating a transformative phase, shifting from traditional mineral-based products to a diversified specialty ingredients and battery materials focus. Management's confidence stems from strategic initiatives, including the acquisition of Nutrition Supplies Services and the development of a battery materials plant, which are expected to enhance global market reach and operational capabilities. Despite facing short-term supply constraints and inflationary pressures, the company's long-term growth outlook remains supported by strong demand in core segments and the scaling of high-value product lines. Vista's financial outlook anticipates moderated revenue growth and stable margins, reflecting the execution risks associated with significant capital expenditures and the transition to new product lines. The industry context, characterized by improving pricing power and a favorable growth trajectory for Indian CDMOs, further supports Sudeep's strategic positioning. Over the next 12-24 months, key opportunities include the successful operationalization of new facilities and the expansion into the battery materials market, while watchpoints include potential raw material shortages and execution risks related to capital projects
Why We Like This Stock
- Successful acquisition of NSS enhances advanced formulation capabilities and expands European market reach
- Development of the battery materials plant is expected to drive significant future earnings and competitive positioning
- Strong demand in the Specialty Ingredients segment supports revenue growth and margin stability
Things To Watch Out For
- Execution risks related to significant capital expenditures may impact short-term performance
- Inflationary pressures and supply-side constraints could hinder operational efficiency
- Dependence on successful commissioning of new facilities for long-term growth may pose risks
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 459 | 502 | 642 | 689 | 786 |
| Profit Before Tax (Cr.) | 175 | 183 | 228 | 244 | 278 |
| PBT Margin | 38.1% | 36.4% | 35.5% | 35.4% | 35.3% |
| Net Profit (Cr.) | 134 | 140 | 174 | 185 | 211 |
| Earnings Per Share | 11.9 | 12.4 | 15.4 | 16.4 | 18.7 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| Prabhudas Liladhar | ▼ Reduce | 855 | 06-Aug-2026 |
Company Overview
Show Company Profile
Sudeep Pharma Limited manufactures and sells excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries in India, the United States, and internationally. The company provides mineral salts, such as iron, calcium, sodium, zinc, copper, magnesium, manganese, potassium, picolinates, simethicone, and others;It also offers micronutrient premixes and liposomal, encapsulated ingredients, spray-dried formats, granulated ingredients, and triturated for sports nutrition, medical and clinical nutrition, infant nutrition, beverages, fortified staples, functional foods, and dairy products. In addition, the company provides a range of mineral powders and granules for carbonated, non-carbonated, and nutraceutical beverages; tricalcium phosphate, dicalcium phophate, dipotassium phosphate, ferric pyrophosphate, and disodium phosphate. Sudeep Pharma Limited was incorporated in 1989 and is based in Vadodara, India.